
Ronald P Zweemer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8057126/publications.pdf Version: 2024-02-01



PONALD P 7WEEMER

#	Article	IF	CITATIONS
1	Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. Journal of Pathology, 2001, 195, 451-456.	2.1	681
2	An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nature Medicine, 2019, 25, 838-849.	15.2	486
3	Molecular Evidence Linking Primary Cancer of the Fallopian Tube to BRCA1 Germline Mutations. Gynecologic Oncology, 2000, 76, 45-50.	0.6	186
4	Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis. Gynecologic Oncology, 2012, 127, 462-466.	0.6	108
5	SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study. International Journal of Gynecological Cancer, 2019, 29, 829-834.	1.2	102
6	Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC Cancer, 2015, 15, 593.	1.1	88
7	Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer. Cell Stem Cell, 2021, 28, 1380-1396.e6.	5.2	88
8	Genomic and transcriptomic plasticity in treatment-naÃ⁻ve ovarian cancer. Genome Research, 2014, 24, 200-211.	2.4	72
9	Tubal ligation and risk of ovarian cancer. Lancet, The, 2001, 358, 844.	6.3	64
10	Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Familial Cancer, 2003, 2, 73-78.	0.9	60
11	Fallopian Tube Intraluminal Tumor Spread From Noninvasive Precursor Lesions. American Journal of Surgical Pathology, 2013, 37, 1123-1130.	2.1	55
12	Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review. European Journal of Cancer, 2020, 133, 14-21.	1.3	55
13	^{99m} Tc SPECT/CT Versus Planar Lymphoscintigraphy for Preoperative Sentinel Lymph Node Detection in Cervical Cancer: A Systematic Review and Metaanalysis. Journal of Nuclear Medicine, 2015, 56, 675-680.	2.8	47
14	Clinical and genetic evaluation of thirty ovarian cancer families. American Journal of Obstetrics and Gynecology, 1998, 178, 85-90.	0.7	43
15	The influence of the <i>b</i> â€value combination on apparent diffusion coefficient based differentiation between malignant and benign tissue in cervical cancer. Journal of Magnetic Resonance Imaging, 2010, 32, 376-382.	1.9	43
16	Preoperative sentinel node mapping with 99mTc-nanocolloid SPECT–CT significantly reduces the intraoperative sentinel node retrieval time in robot assisted laparoscopic cervical cancer surgery. Gynecologic Oncology, 2013, 129, 389-394.	0.6	42
17	Whole Genome Analysis of Ovarian Granulosa Cell Tumors Reveals Tumor Heterogeneity and a High-Grade TP53-Specific Subgroup. Cancers, 2020, 12, 1308.	1.7	41
18	Methylation profiles of endometrioid and serous endometrial cancers. Endocrine-Related Cancer, 2010, 17, 663-673.	1.6	30

#	Article	IF	CITATIONS
19	Pelvic Lymphadenectomy Improves Survival in Patients With Cervical Cancer With Low-Volume Disease in the Sentinel Node: A Retrospective Multicenter Cohort Study. International Journal of Gynecological Cancer, 2014, 24, 303-311.	1.2	30
20	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative. Clinical Cancer Research, 2017, 23, 1274-1285.	3.2	30
21	The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care—A Systematic Review. Cancers, 2022, 14, 1059.	1.7	30
22	Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in <i>BRCA1/2</i> Pathogenic Variant Carriers. JAMA Oncology, 2021, 7, 1203.	3.4	27
23	Comparative Genomic Hybridization of Microdissected Familial Ovarian Carcinoma: Two Deleted Regions on Chromosome 15q Not Previously Identified in Sporadic Ovarian Carcinoma. Laboratory Investigation, 2001, 81, 1363-1370.	1.7	25
24	Vaginal Radical Trachelectomy for Early-Stage Cervical Cancer: Increased Recurrence Risk for Adenocarcinoma. International Journal of Gynecological Cancer, 2016, 26, 1293-1299.	1.2	25
25	Survival analysis in familial ovarian cancer, a case control study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2001, 98, 219-223.	0.5	21
26	Increasing experience in laparoscopic staging of early ovarian cancer. Gynecological Surgery, 2012, 9, 89-96.	0.9	20
27	Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer. The Cochrane Library, 2018, 2018, CD012567.	1.5	19
28	Robotic Surgery for Gynaecologic Cancer: An Overview. Current Oncology Reports, 2012, 14, 544-549.	1.8	16
29	99mTc-Nanocolloid SPECT/MRI Fusion for the Selective Assessment of Nonenlarged Sentinel Lymph Nodes in Patients with Early-Stage Cervical Cancer. Journal of Nuclear Medicine, 2016, 57, 551-556.	2.8	16
30	Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer. Familial Cancer, 2022, 21, 295-304.	0.9	15
31	Ovarian abscess during pregnancy mimicking a leiomyoma of the uterus: A complication of transvaginal ultrasound-guided oocyte aspiration. Journal of Assisted Reproduction and Genetics, 1996, 13, 81-85.	1.2	14
32	Detection of cervical cancer recurrence during follow-up: A multivariable comparison of 9 frequently investigated serum biomarkers. Gynecologic Oncology, 2013, 131, 655-660.	0.6	14
33	High-resolution T2-weighted cervical cancer imaging: a feasibility study on ultra-high-field 7.0-T MRI with an endorectal monopole antenna. European Radiology, 2017, 27, 938-945.	2.3	13
34	Women Harboring BRCA1/2 Germline Mutations are at Risk for Breast and Female Adnexal Carcinoma. International Journal of Gynecological Pathology, 2003, 22, 315.	0.9	12
35	Ovarian carcinogenesis, an alternative theory. Gynecologic Oncology, 2007, 107, 355-355.	0.6	12
36	Upstaging by para-aortic lymph node dissection in patients with locally advanced cervical cancer: A systematic review and meta-analysis. Gynecologic Oncology, 2022, 164, 667-674.	0.6	12

RONALD P ZWEEMER

#	Article	IF	CITATIONS
37	The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy. Familial Cancer, 2015, 14, 539-544.	0.9	11
38	Shortâ€ŧerm surgical complications after radical hysterectomy—A nationwide cohort study. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 925-932.	1.3	11
39	FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring. Gynecologic Oncology, 2021, 162, 413-420.	0.6	11
40	Response to Systemic Therapies in Ovarian Adult Granulosa Cell Tumors: A Literature Review. Cancers, 2022, 14, 2998.	1.7	11
41	Indocyanine green versus technetiumâ€99m with blue dye for sentinel lymph node detection in earlyâ€stage cervical cancer: A systematic review and metaâ€analysis. Cancer Reports, 2022, 5, e1401.	0.6	10
42	The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis. Gynecologic Oncology, 2021, 161, 876-883.	0.6	10
43	Treatment of bulky lymph nodes in locally advanced cervical cancer: boosting versus debulking. International Journal of Gynecological Cancer, 2022, 32, 861-868.	1.2	9
44	In Vitro Systematic Drug Testing Reveals Carboplatin, Paclitaxel, and Alpelisib as a Potential Novel Combination Treatment for Adult Granulosa Cell Tumors. Cancers, 2021, 13, 368.	1.7	8
45	Genomic aberrations relate early and advanced stage ovarian cancer. Cellular Oncology (Dordrecht), 2012, 35, 181-188.	2.1	7
46	Feasibility of a drop-in γ-probe for radioguided sentinel lymph detection in early-stage cervical cancer. EJNMMI Research, 2022, 12, .	1.1	7
47	Screening to improve ovarian cancer prognosis?. Lancet, The, 2016, 387, 921-923.	6.3	5
48	Prognostic value of radiological recurrence patterns in ovarian cancer. Gynecologic Oncology, 2020, 157, 606-612.	0.6	5
49	Distinct Genomic Profiles Are Associated with Treatment Response and Survival in Ovarian Cancer. Cancers, 2022, 14, 1511.	1.7	5
50	Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2016, 115, 1174-1178.	2.9	4
51	Bedside Ultrasound Confirmation of Incisional Port Hernia. Journal of Minimally Invasive Gynecology, 2017, 24, 190.	0.3	4
52	[18F]FDG and [18F]FES positron emission tomography for disease monitoring and assessment of anti-hormonal treatment eligibility in granulosa cell tumors of the ovary. Oncotarget, 2021, 12, 665-673.	0.8	4
53	No Value for Routine Chest Radiography in the Work-Up of Early Stage Cervical Cancer Patients. PLoS ONE, 2015, 10, e0131899.	1.1	4
54	Familial Ovarian Cancer. , 2001, 39, 13-24.		3

Familial Ovarian Cancer., 2001, 39, 13-24. 54

Ronald P Zweemer

#	Article	IF	CITATIONS
55	Identifying patients with a history of ovarian cancer for referral for genetic counselling: non-randomised comparison of two case-finding strategies in primary care. British Journal of General Practice, 2018, 68, e750-e756.	0.7	3
56	The diagnostic process of cervical cancer; areas of good practice, and windows of opportunity. Gynecologic Oncology, 2015, 138, 405-410.	0.6	2
57	Robot-assisted laparoscopic debulking surgery for recurrent adult granulosa cell tumors. Gynecologic Oncology Reports, 2021, 37, 100783.	0.3	2
58	Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy. Gynecologic Oncology, 2021, 163, 371-377.	0.6	2
59	Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian, fallopian tube and/or primary peritoneal cancer. The Cochrane Library, 0, , .	1.5	1
60	Patient engagement in research on rare gynecological tumors. International Journal of Gynecological Cancer, 2020, 30, 2012-2014.	1.2	1
61	Familial Occurrence of Adult Granulosa Cell Tumors: Analysis of Whole-Genome Germline Variants. Cancers, 2021, 13, 2430.	1.7	1
62	Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors. Supportive Care in Cancer, 2022, 30, 3409-3418.	1.0	1
63	Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study. Gynecologic Oncology, 2022, 165, 339-346.	0.6	1
64	Re: The Association Between Hysterectomy and Ovarian Cancer Risk: A Population-Based Record-Linkage Study. Journal of the National Cancer Institute, 2019, 111, 1361-1361.	3.0	0